ClinicalTrials.gg
CompletedNCT04110886Updated Feb 9, 2021

Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers

A Phase 1 interventional study of HSK21542 and Placebo in Postoperative Pain and Chronic Pain, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-09.

Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Pain, Postoperative with a site in Australia — 6 open to participants now, 6 under way, 2 of them phase 3. Pain, Postoperative · Australia.

Enrollment
10th of 19
120 · median 120
Started
2020
with 2 others
Phase 1
4 of 21
1 open now
Registered
12th of 21
by date

Among the 21 studies in Pain, Postoperative with a site in Australia, this one is the 10th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 1, and was the 12th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

6 of the 21 studies in Pain, Postoperative with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Pain, Postoperative with a site in Australia, or all of them as a file.
02

Study summary

This is a A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a kappa receptor agonist HSK21542 in Healthy Volunteers.

The study will enroll approximately 50 adults. The anticipated study duration will be up to 6 months.

03

Conditions studied

  • Postoperative Pain
  • Chronic Pain

Keywords

  • Pain
  • Postoperative Pain
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects, age 18-45 years;
  • between 18.0-27.0 kg/m2
  • Determined by investigator to be in general good health according to medical history, comprehensive physical examination;
  • Understanding of the nature, significance, potential benefits and risks of the trial, understanding of the procedures and be able to provide written voluntarily ;
  • Good communication with investigators, compliance with the study requirements and willingness to stay in phase I clinical trial ward as required.

Exclusion criteria

Exclusion Criteria:

  • Anyone who has suffered or is currently suffering from any serious diseases, that may interfere with the results of the trial;
  • Determined by investigator to be abnormal with clinical significance in Physical examination, vital signs monitoring, , chest radiograph, laboratory examination;
  • positive, antibody positive, Treponema pallidum antibody positive, or antibody positive;
  • > 450ms;
  • Allergic constitution;
  • Intolerance of venipuncture and/or history of haemorrhage or needle fainting;
  • Drug or alcohol abuse;
  • Have used any prescription, over-the-counter, Chinese herbal medicine or health products within 14 days;
  • Blood donation or massive bleeding within 3 months (greater than 450 mL);
  • Participants in any drug clinical trial within 3 months.
  • Birth planning in the next six months.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    HSK21542 single ascending doses

    Drug: HSK21542

  • Placebo comparator
    Placebo single dose

    Drug: Placebo

Interventions

  • Single dose, injection, starting dose of 0.2ug escalating up to 20ug

  • DrugPlacebo

    Single dose, injection matching placebo

06

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events

    To evaluate the safety and tolerability of HSK21542 in comparison with placebo after a single injection in healthy subjects in terms of adverse events

    Time frame: Between screening and 7-9 days after dosing

  2. Number of subjects with abnormal physical examination/ abnormal vital signs/ abnormal laboratory parameters

    To evaluate the safety and tolerability of HSK21542 in comparison with placebo after a single injection in healthy subjects in terms of abnormal physical examination/ abnormal vital signs/ abnormal laboratory parameters

    Time frame: Between screening and 7-9 days after dosing

Secondary outcomes

  1. Cmax

    Maximum (peak) plasma drug concentration

    Time frame: From the start of administration to 24 hours after administration

  2. Tmax

    Time to reach maximum (peak) plasma concentration following drug administration

    Time frame: From the start of administration to 24 hours after administration

  3. t1/2

    Elimination half-life

    Time frame: From the start of administration to 24 hours after administration

  4. AUC0-t

    Area under the plasma concentration-time curve from time zero to time t.

    Time frame: From the start of administration to 24 hours after administration

  5. AUC0-inf

    Area under the plasma concentration-time curve from time zero to infinity

    Time frame: From the start of administration to 24 hours after administration

  6. CL

    Apparent total body clearance of the drug from plasma

    Time frame: From the start of administration to 24 hours after administration

  7. Vd

    Apparent volume of distribution

    Time frame: From the start of administration to 24 hours after administration

07

Study locations

1 site
  • CMAX Clinical Research Pty Ltd
    Adelaide, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Dec 2020, 5 months.

Of 83 phase 1 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2019
First posted
Oct 1, 2019
StartActual
Jul 2, 2020
Primary completionActual
Dec 8, 2020
CompletionActual
Jan 5, 2021
Last update
Feb 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04110886
Responsible party
Sponsor
First posted
Oct 1, 2019
Start date
Jul 2, 2020
Primary completion
Dec 8, 2020
Completion
Jan 5, 2021
Last update
Feb 9, 2021

Study contacts

Paul Wabnitz, PhD
principal investigator · CMAX Clinical Research Pty Ltd

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anrikefon

Start the discussion